KCRS23 Presentations & Video
Each video is the full session length; to jump to a particular presentation, note the timestamp in red beneath the speaker’s name.
To view slide presentations, click the icon or presentation title.
BIOMARKERS SYMPOSIUM
Session 1: Biomarker Technologies in RCC
Moderated by Toni Choueiri, DFCI & Mahrukh Huseni, Genentech
Genomic DNA/RNA Biomarkers
Ari Hakimi, Memorial Sloan Kettering
(Video presentation begins at 00:45)
Spatial Biomarkers: Tissue-Based in situ Analyses Including IF for Biomarker Development
(Video presentation begins at 12:20)
High-Dimensional/Spatial Tools for Biomarker Discovery in RCC
(Video presentation begins at 25:30)
How Can AI Guide Biomarker Development and Progress in RCC
(Video presentation begins at 37:35)
Developing Metabolic Imaging Agents in Kidney Cancer
(Video presentation begins at 50:20)
CT-Based Radiomics Model for the Prediction of Genomic Alterations in Renal Cell Carcinoma (RCC)
(Video presentation begins at 1:00:45)
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab Plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
(Video presentation begins at 1:05:25)
Note presentation time stamps to locate specific speakers.
Biomarkers Session One Q&A begins at 1:10:55.
BIOMARKERS SYMPOSIUM
Session 2: Clinical Biomarkers: Trial Data and Directions
Moderated by Medhi Mollapour, State University of New York, and Tom Powles, Barts Cancer Centre
Emerging Biomarkers for the Ipi/Nivo: New Data from PRISM
Tom Powles, Barts Cancer Centre
(Video presentation begins at 01:06)
Learning from the Atezolizumab Biomarker Program in RCC: Lessons for Future Trial Designs
David McDermott, Beth Israel Deaconess Medical Center
(Video presentation begins at 11:20)
Biomarkers for PD-1 Based Therapies in RCC
Saurabh Gupta, Bristol Myers Squibb
(Video presentation begins at 23:15)
Designing Clinical Trials in the Perioperative Setting in RCC
Axel Bex, Royal Free Hospital London
(Video presentation begins at 35:40)
Development and Clinical Application of ctDNA in RCC
Sylvan Baca, Dana-Farber Cancer Institute
(Video presentation begins at 46:20)
Biomarkers of Toxicity to Immune Checkpoint Blockers
Alexander Gusev, Dana-Farber Cancer Institute
(Video presentation begins at 56:05)
KIM 1 and Kidney Cancer: Multiple Setting or an Ideal Setting?
Wenxin (Vincent) Xu, Dana-Farber Cancer Institute
(Video presentation begins at 1:07:05)
Utilization of ctDNA for RCC Disease Monitoring and Treatment Response
Adam ElNaggar, Natera
(Video presentation begins at 1:18:35)
Note presentation time stamps to locate specific speakers.
Biomarkers Session Two Q&A begins at 1:28:30.
MENTORSHIP & SPONSORSHIP
Challenges and Opportunities
Moderated by Hans Hammers, UTSW, and Tom Powles, Barts Cancer Centre
Session 1: Modulating Tumor Microenvironment in Kidney Cancer
Moderated by: Eric Jonasch, MDACC & Ari Hakimi, MSKCC
The Bone Metastasis Immunological Niche: Unraveling Its Complexity and Role in Therapy Response and Resistance
Eleonora Dondossola, MD Anderson Cancer Center
(Video presentation begins at 01:35)
Metabolic Demands and Determinants in the RCC Tumor Microenvironment
Kimryn Rathmell, Vanderbilt University Medical Center
(Video presentation begins at 14:55)
Identifying Novel Immune Evasion Tumor Immune Networks as Targets for ccRCC Immunotherapy
Hartland Jackson, Samuel Lunenfeld Research Institute
(Video presentation begins at 32:30)
Targeting a Combined VHL and 3p Chromatin Remodeler Deficit in Renal Cell Carcinoma
Ruhee Dere, Baylor College of Medicine
(Video presentation begins at 46:10)
Session 2: Biology of Non-Clear Cell Subtypes
Moderated by: Srinivas Viswanathan, DFCI & Elizabeth Henske, Brigham & Women’s
Defining Cellular and Genetic Factors for Renal Cell Carcinoma Subtypes
Jung Wook Park, Duke Cancer Institute
(Video presentation begins at 00:35)
Targeting GPNMB in Renal Tumors in Tuberous Sclerosis Complex and Translocation Renal Cell Carcinoma
Kaushal Asrani, Johns Hopkins University
(Video presentation begins at 16:15)
Deep Functional Characterization of MiT/TFE Fusions in Translocation Renal Cell Carcinoma
Srinivas Viswanathan, Dana-Farber Cancer Institute
(Video presentation begins at 29:40)
Targeting TFEB and TFE3 in Renal Tumorigenesis
Elizabeth Henske, Brigham and Women’s Hospital
(Video presentation begins at 45:15)
Session 3: Trials in Progress: Moving the Needle
Moderated by: Robert Motzer, MSKCC & Naomi Haas, Abramson Cancer Center
Zanzalintinib in Combination with Immune Checkpoint Inhibitors: Design of the Renal Cell Carcinoma Expansion Stage Cohorts in STELLAR-002
Neil Shah, Memorial Sloan Kettering
(Video presentation begins at 00:50)
LITESPARK-024: A Randomized Phase 1/2 Study of Belzutifan with or without Palbociclib for Previously Treated Advanced Renal Cell Carcinoma
David McDermott, Beth Israel
(Video presentation begins at 05:40)
SAMETA: A Phase III Study of Savolitinib + Durvalumab vs Sunitinib and Durvalumab Monotherapy in Patients with MET-Driven, Unresectable, Locally Advanced/Metastatic Papillary Renal Cell Carcinoma
Toni Choueiri, Dana-Farber Cancer Institute
(Video presentation begins at 09:00)
A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of NKT2152, an Orally Administered HIF2α Inhibitor, to Investigate Safety, PK, PD and Clinical Activity in Patients with Advanced ccRCC
Toni Choueiri, Dana-Farber Cancer Institute
(Video presentation begins at 14:15)
NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Rana McKay, UC San Diego
(Video presentation begins at 17:05)
STARLITE 1: Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC
Eric Jonasch, MD Anderson
(Video presentation begins at 22:45)
Phase 1/2 Study of PRO1160, a CD70-Directed Antibody-drug Conjugate, in Patients with Advanced Solid Tumors and Hematologic Malignancies
Eric Jonasch, MD Anderson
(Video presentation begins at 26:35)
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (Adenosine A2a Receptor Antagonist) in First-Line Advanced Renal Cell Carcinoma
Katy Beckermann, Vanderbilt University Medical Center
(Video presentation begins at 29:30)
Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)
Katy Beckermann, Vanderbilt University Medical Center
(Video presentation begins at 33:15)
Note presentation time stamps to locate specific speakers.
Session Three Q&A begins at 37:20.
BREAKING BARRIERS TO TRIAL ENROLLMENT
Special Session Four
Moderated by Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center
The panelists discussed the challenges and opportunities in clinical trial enrollment, focusing on how to decrease barriers of entry for kidney cancer patients. They explored strategies to make clinical trials more inclusive for all kidney cancer patients, regardless of race, age, location, or gender, which are all currently limiting access. The panelists also shared their insights on the role of regulatory bodies, pharmaceutical companies, and healthcare providers in facilitating trial enrollment.
This session provided a platform for open dialogue and exchange of ideas to improve patient access to clinical trials, a critical step in accelerating cures for kidney cancer.
FEATURED SPEAKER:
New Directions in Basic Kidney Cancer Research
William G. Kaelin, Jr., MD
Sidney Farber Professor of Medicine, Harvard Medical School
New Directions in Basic Kidney Cancer Research
Dr. Kaelin is a professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute. He was awarded the Nobel Prize in Physiology or Medicine in 2019 for his discoveries of how cells sense and adapt to oxygen availability. His research has opened new therapeutic strategies for the treatment of various cancers.
SESSION 5: Clinical and Scientific Updates in Kidney Cancer
Moderated by: Tony Choueiri, Dana-Farber Cancer Institute
Front Line Systemic Therapy Sessions
Tom Powles, Barts Cancer Centre
(Video presentation begins at 00:45)
Subsequent Line Treatments for Advanced Disease
Robert Motzer, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 13:00)
Adjuvant Treatment Options
Bradley McGregor, Dana-Farber Cancer Institute
(Video presentation begins at 28:15)
Radiation Therapy Strategies in RCC
Raquibul Hannan, UTSW
(Video presentation begins at 38:30)
Strategies for Patients with Non-Clear Cell RCC
Chung-Han Lee, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 49:40)
Novel Therapies Outside Immunotherapy
Rana McKay, University of California (San Diego)
(Video presentation begins at 1:00:45)
Novel Immunotherapy Strategies
David Braun, Yale
(Video presentation begins at 1:15:10)
Note presentation time stamps to locate specific speakers.
Session Five Q&A begins at 1:24:30.
SESSION 6: Immunotherapy Advances and Research
Moderated by: Hans Hammers, UTSW & David Braun, Yale
CAR T Therapies for RCC: What We've Learned
Avery Posey, Penn Medicine
(Video presentation begins at 00:50)
Targeting Interleukin-1beta to Overcome Adaptive Immune Resistance in Renal Cell Carcinoma
Matthew Dallos, MSKCC
(Video presentation begins at 25:00)
Targeting RNA Sensing to Enhance Immunotherapy Responses in Kidney Cancer
John Wilson, Vanderbilt
(Video presentation begins at 40:55)
A Novel STAT3 Antisense Oligonucleotide-Based Immunotherapy for Renal Cell Carcinoma
Marice Alcantara, City of Hope
(Video presentation begins at 52:55)
Derepression of Human Endogenous Retrovirus and Implications for Immunotherapy for Clear Cell Renal Cell Carcinoma
Qinqin Jiang, DFCI
(Video presentation begins at 1:04:30)
SESSION 7: Oral Abstract Presentations
Moderated by: Rana McKay, UC, San Diego & Joshua Lang, Univ. of Wisconsin
Final Database Lock Results of the Phase 2 Cohort of Lenvatinib + Pembrolizumab for Progressive Disease after a PD-1/PD-L1-Containing Therapy in Metastatic Clear Cell Renal Cell Carcinoma
Chung-Han Lee, MSKCC
(Video presentation begins at 01:20)
ORCHID: A Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations
Yasser Ged, Johns Hopkins
(Video presentation begins at 09:15)
Circulating KIM-1 is a Minimally Invasive Biomarker Correlated with Treatment Response to Nivolumab in Patients with Metastatic Renal Cell Carcinoma
Wenxin (Vincent) Xu, DFCI
(Video presentation begins at 28:55)
Functional and Translational Consequences of Immunometabolic Coevolution in ccRCC
Ed Reznik, MSKCC
(Video presentation begins at 36:15)
Host Immune Signatures as Predictors of Response to Immunotherapy-Based Regimens in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Eddy Saad, DFCI
(Video presentation begins at 57:45)
Spatial Proteomics Enables Identification of Prognostic Biomarkers in Papillary Renal Cell Carcinoma
Anupama Reddy, Vindhya Data Science Inc.
(Video presentation begins at 1:06:00)
Note presentation time stamps to locate specific speakers.
Session Seven is structured with two presentations, followed by Q&A, then two more presentations, etc. The Q&A sessions are at 18:00, 44:20, and 1:15:30.
SESSION 8: Rapid Abstract Presentations
Moderated by: Sumanta Pal, City of Hope & Deepak Kilari, Medical College of Wisconsin
Dissection of Tumor-Intrinsic and Tumor-Extrinsic Features of MiT/TFE Translocation Renal Cell Carcinoma Via Single-Cell RNA Sequencing
Prathyusha Konda, DFCI
(Video presentation begins at 00:35)
Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic Neoplasms
Chris Labaki, DFCI
(Video presentation begins at 06:00)
Epigenomic Profiling Nominates Master Transcription Factors (TFs) Driving Sarcomatoid Differentiation (SD) of Renal Cell Carcinoma (RCC)
Karl Semaan, DFCI
(Video presentation begins at 10:45)
A Modified IL-18 Drug in Combination with CTLA-4 Blockade Enhances Anti-Tumor Efficacy in Preclinical Models of Renal Cell Carcinoma
David Schoenfeld, Yale
(Video presentation begins at 22:35)
The Identification of a Novel Orally Available Ferroptosis Inducer for the Treatment of Clear Cell Renal Carcinoma
Mei Koh, Kuda Therapeutics, Inc.
(Video presentation begins at 28:25)
The Impact of Insurance Status on Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Daniela Castro, City of Hope
(Video presentation begins at 38:20)
Examining Trends in Kidney Cancer Mortality by Gender and Race in the United States: A 20-Year AnalysisccRCC
Chinmay Jani, Univ. of Miami
(Video presentation begins at 44:35)
Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
George Gebrael, Huntsman
(Video presentation begins at 50:00)
Note presentation time stamps to locate specific speakers.
Session Eight is structured with three presentations, followed by Q&A, then more presentations, etc. The Q&A sessions are at 15:55, 34:40, and 54:40.
Special Session for Investigators: Expert Insights on the Research Funding Landscape
Writing a Grant: The NCI Perspective
(Video presentation begins at 00:30)
CDMRP Grant Proposals: Tips for the First Time Applicant
(Video presentation begins at 35:30)
ARPA-H Opportunities for Research Funding
(Video presentation begins at 1:11:20)